24 Sep Amphivena Closes $62 Million Series C Financing to Expand the Clinical Development of AMV564 into Solid Tumors and to Develop its T Cell Engagement Portfolio
South San Francisco, CA —September 24, 2019 -- Amphivena Therapeutics, Inc., a private clinical stage immuno-oncology company developing T cell engager therapeutics for cancer, announced today the closing of a $62 million Series C financing. The round was co-led by NanoDimension and Qiming Venture Partners...